Search

Categories

    • categories-img Jacket, Women
    • categories-img Woolend Jacket
    • categories-img Western denim
    • categories-img Mini Dresss
    • categories-img Jacket, Women
    • categories-img Woolend Jacket
    • categories-img Western denim
    • categories-img Mini Dresss
    • categories-img Jacket, Women
    • categories-img Woolend Jacket
    • categories-img Western denim
    • categories-img Mini Dresss
    • categories-img Jacket, Women
    • categories-img Woolend Jacket
    • categories-img Western denim
    • categories-img Mini Dresss
    • categories-img Jacket, Women
    • categories-img Woolend Jacket
    • categories-img Western denim
    • categories-img Mini Dresss

Filter By Price

$
-
$

Dietary Needs

Top Rated Product

product-img product-img

Modern Chair

$165.00
product-img product-img

Plastic Chair

$165.00
product-img product-img

Design Rooms

$165.00

Brands

  • Wooden
  • Chair
  • Modern
  • Fabric
  • Shoulder
  • Winter
  • Accessories
  • Dress

Welcome and thank you for visiting us. For any query call us on 0799 626 359 or Email [email protected]

Offcanvas Menu Open

Shopping Cart

Africa largest book store

Sub Total:

Search for any Title

Therapeutic Development in the Absence of Predictive Animal Models of Nervous System Disorders : Proceedings of a Workshop

By: (Author) Board on Health Sciences Policy , (Author) and Medicine National Academies of Sciences Engineering , (Author) Forum on Neuroscience and Nervous System Disorders , (Author) Health and Medicine Division , (Edited by) Clare Stroud , (Edited by) Lisa Bain , (Edited by) Noam I. Keren , (Edited by) Sheena M. Posey Norris

Extended Catalogue

Ksh 9,900.00

Format: Paperback or Softback

ISBN-10: 0309455138

ISBN-13: 9780309455138

Publisher: National Academies Press

Imprint: National Academies Press

Country of Manufacture: GB

Country of Publication: GB

Publication Date: Jun 24th, 2017

Print length: 94 Pages

Product Classification: Medicine

Choose your Location

Shipping & Delivery

Door Delivery

Delivery fee

Delivery in 10 to 14 days

  • Description

  • Reviews

Compared with other disease areas, central nervous system (CNS) disorders have had the highest failure rate for new compounds in advanced clinical trials. Most CNS drugs fail because of efficacy, and the core issue underlying these problems is a poor understanding of disease biology. Concern about the poor productivity in neuroscience drug development has gained intensity over the past decade, amplified by a retraction in investment from the pharmaceutical industry. This retreat by industry has been fueled by the high failure rate of compounds in advanced clinical trials for nervous system disorders. In response to the de-emphasis of CNS disorders in therapeutic development relative to other disease areas such as cancer, metabolism, and autoimmunity, the National Academies of Sciences, Engineering, and Medicine initiated a series of workshops in 2012 to address the challenges that have slowed drug development for nervous system disorders. Motivated by the notion that advances in genetics and other new technologies are beginning to bring forth new molecular targets and identify new biomarkers, the Academies hosted the third workshop in this series in September 2016. Participants discussed opportunities to accelerate early stages of drug development for nervous system disorders in the absence of animal models that reflect disease and predict efficacy. This publication summarizes the presentations and discussions from the workshop. Table of ContentsFront Matter1 Introduction and Overview2 Drug Development for Nervous System Disorders: Overview of Challenges and Potential Opportunities3 Case Studies: Therapeutic Development for Parkinson's Disease and Schizophrenia in the Absence of Predictive Animal Models of Disease4 New Modeling Approaches for Nervous System Disorders5 Private-Sector Thresholds for Investment in Neuroscience Clinical Trials6 Ethical Considerations7 Regulatory PerspectivesAppendix A: ReferencesAppendix B: Workshop AgendaAppendix C: Registered Attendees

Compared with other disease areas, central nervous system (CNS) disorders have had the highest failure rate for new compounds in advanced clinical trials. Most CNS drugs fail because of efficacy, and the core issue underlying these problems is a poor understanding of disease biology. Concern about the poor productivity in neuroscience drug development has gained intensity over the past decade, amplified by a retraction in investment from the pharmaceutical industry. This retreat by industry has been fueled by the high failure rate of compounds in advanced clinical trials for nervous system disorders.

In response to the de-emphasis of CNS disorders in therapeutic development relative to other disease areas such as cancer, metabolism, and autoimmunity, the National Academies of Sciences, Engineering, and Medicine initiated a series of workshops in 2012 to address the challenges that have slowed drug development for nervous system disorders. Motivated by the notion that advances in genetics and other new technologies are beginning to bring forth new molecular targets and identify new biomarkers, the Academies hosted the third workshop in this series in September 2016. Participants discussed opportunities to accelerate early stages of drug development for nervous system disorders in the absence of animal models that reflect disease and predict efficacy. This publication summarizes the presentations and discussions from the workshop.


Get Therapeutic Development in the Absence of Predictive Animal Models of Nervous System Disorders by at the best price and quality guranteed only at Werezi Africa largest book ecommerce store. The book was published by National Academies Press and it has pages. Enjoy Shopping Best Offers & Deals on books Online from Werezi - Receive at your doorstep - Fast Delivery - Secure mode of Payment

Customer Reviews

Based on 0 reviews

Mind, Body, & Spirit